Frequency of infusion-related reactions with CPX-351 treatment in an observational study in adults with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes (AML-MRC)

Meagan A. Jacoby; Laura Finn; Ashkan Emadi; Nakhle S. Saba; Bayard L. Powell; Karen Seiter; Rosella Garcia; Stefan Faderl; Heather J. Male

doi:10.1080/10428194.2021.1919668

Frequency of infusion-related reactions with CPX-351 treatment in an observational study in adults with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes (AML-MRC)

Meagan A. Jacoby, Laura Finn, Ashkan Emadi, Nakhle S. Saba, Bayard L. Powell, Karen Seiter, Rosella Garcia, Stefan Faderl, Heather J. Male

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	2539-2542
Number of pages	4
Journal	Leukemia and Lymphoma
Volume	62
Issue number	10
DOIs	https://doi.org/10.1080/10428194.2021.1919668
State	Published - 2021

Access to Document

10.1080/10428194.2021.1919668

Cite this

Jacoby, M. A., Finn, L., Emadi, A., Saba, N. S., Powell, B. L., Seiter, K., Garcia, R., Faderl, S., & Male, H. J. (2021). Frequency of infusion-related reactions with CPX-351 treatment in an observational study in adults with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes (AML-MRC). Leukemia and Lymphoma, 62(10), 2539-2542. https://doi.org/10.1080/10428194.2021.1919668

Jacoby, Meagan A. ; Finn, Laura ; Emadi, Ashkan ; Saba, Nakhle S. ; Powell, Bayard L. ; Seiter, Karen ; Garcia, Rosella ; Faderl, Stefan ; Male, Heather J. / Frequency of infusion-related reactions with CPX-351 treatment in an observational study in adults with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes (AML-MRC). In: Leukemia and Lymphoma. 2021 ; Vol. 62, No. 10. pp. 2539-2542.

@article{a2542c0ca92c4668a13d2cc4cfaa434f,

title = "Frequency of infusion-related reactions with CPX-351 treatment in an observational study in adults with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes (AML-MRC)",

author = "Jacoby, {Meagan A.} and Laura Finn and Ashkan Emadi and Saba, {Nakhle S.} and Powell, {Bayard L.} and Karen Seiter and Rosella Garcia and Stefan Faderl and Male, {Heather J.}",

note = "Funding Information: The authors thank all the patients who participated in the study and their families, as well as the investigators, nurses, coordinators, and other research staff at each study site. Medical writing and editorial assistance were provided by Christina Sanders, PhD, of Cello Health Communications/SciFluent Communications, Inc., and were financially supported by Jazz Pharmaceuticals. ",

year = "2021",

doi = "10.1080/10428194.2021.1919668",

language = "English",

volume = "62",

pages = "2539--2542",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

number = "10",

}

Jacoby, MA, Finn, L, Emadi, A, Saba, NS, Powell, BL, Seiter, K, Garcia, R, Faderl, S & Male, HJ 2021, 'Frequency of infusion-related reactions with CPX-351 treatment in an observational study in adults with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes (AML-MRC)', Leukemia and Lymphoma, vol. 62, no. 10, pp. 2539-2542. https://doi.org/10.1080/10428194.2021.1919668

Frequency of infusion-related reactions with CPX-351 treatment in an observational study in adults with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes (AML-MRC). / Jacoby, Meagan A.; Finn, Laura; Emadi, Ashkan; Saba, Nakhle S.; Powell, Bayard L.; Seiter, Karen; Garcia, Rosella; Faderl, Stefan; Male, Heather J.

In: Leukemia and Lymphoma, Vol. 62, No. 10, 2021, p. 2539-2542.

Research output: Contribution to journal › Letter › peer-review

TY - JOUR

T1 - Frequency of infusion-related reactions with CPX-351 treatment in an observational study in adults with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes (AML-MRC)

AU - Jacoby, Meagan A.

AU - Finn, Laura

AU - Emadi, Ashkan

AU - Saba, Nakhle S.

AU - Powell, Bayard L.

AU - Seiter, Karen

AU - Garcia, Rosella

AU - Faderl, Stefan

AU - Male, Heather J.

N1 - Funding Information: The authors thank all the patients who participated in the study and their families, as well as the investigators, nurses, coordinators, and other research staff at each study site. Medical writing and editorial assistance were provided by Christina Sanders, PhD, of Cello Health Communications/SciFluent Communications, Inc., and were financially supported by Jazz Pharmaceuticals.

PY - 2021

Y1 - 2021

UR - http://www.scopus.com/inward/record.url?scp=85106010696&partnerID=8YFLogxK

U2 - 10.1080/10428194.2021.1919668

DO - 10.1080/10428194.2021.1919668

M3 - Letter

C2 - 33974493

AN - SCOPUS:85106010696

VL - 62

SP - 2539

EP - 2542

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 10

ER -

Frequency of infusion-related reactions with CPX-351 treatment in an observational study in adults with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes (AML-MRC)

Access to Document

Other files and links

Cite this